EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT05584319
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05584319
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05584319. Randomized; no masking; primary purpose treatment. Start 2022-12-15 (anticipated); primary completion 2024-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction
- Condition
- Heart Failure
- Intervention (Drug)
- Empagliflozin 10 Mg
- Lead sponsor
- Zhijun Sun
Record details
- Record id
cardio:ct-nct05584319- Content hash
b760d0ce9d1409e89dd89cd0a2b1fad6d37febdd284aff153811fa24d72908b5